VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2018 | Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma

Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Nathan Fowler, MD, of the MD Anderson Cancer Center, Houston, TX, discusses these results and their importance here.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter